-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
New Releases for the Year of the Horse: Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical Receives Concurrent Approval for Two Active Pharmaceutical Ingredients—Metoclopramide Hydrochloride and Metoclopramide—in a Single Day
Category:
发布时间：2026-02-27
【概要描述】
On February 27, the active pharmaceutical ingredients metoclopramide hydrochloride and metoclopramide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, successfully had their registration status at the Center for Drug Evaluation of the National Medical Products Administration changed to “A,” thereby qualifying as APIs for use in marketed dosage forms. Since the beginning of this year, the Group has received approval for a total of five new specialty API products.
On February 27, the active pharmaceutical ingredients metoclopramide hydrochloride and metoclopramide, developed by Hebei Guangxiang Pharmaceutical Co., Ltd. of Shijiazhuang Sihua Pharmaceutical Group, successfully changed their registration status to “A” at the Center for Drug Evaluation of the National Medical Products Administration, thereby qualifying as APIs for use in marketed dosage forms. Since the beginning of this year, the Group has received approval for a total of five new specialty API products.
According to available information, metoclopramide hydrochloride and metoclopramide are dopamine D2 receptor antagonists that also exhibit agonistic activity at serotonin 5-HT4 receptors, thereby promoting gastrointestinal motility. The primary indication for these agents is the control of emesis, and they are used to treat nausea, belching, gastric distension, and reflux esophagitis, among other conditions.
In recent years, the Group has positioned itself in both domestic and international markets, continuously deepening its integrated innovation strategy that combines active pharmaceutical ingredients (APIs) with finished dosage forms. It has driven the high-end development of injectables, the diversification of oral formulations, and the specialized advancement of APIs, gradually building a robust product portfolio spanning anti-infectives, antivirals, respiratory, neurological, renal, cardiovascular and cerebrovascular, gastrointestinal, anesthetic, and endocrine therapeutic areas. At the same time, leveraging process optimization and digital transformation, the Group has steadily strengthened its API quality and cost advantages, establishing itself as a reliable partner for numerous formulation manufacturers. To date, the Group boasts 96 API products, with Guangxiang Pharmaceutical accounting for 54 of them, thereby injecting strong momentum into the company’s innovative, high-quality growth.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091